Compare Citius Pharmaceuticals Inc (CTXR) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs W W Grainger Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.75 (market cap $20.01M), while W W Grainger Inc trades at $1,308.84 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 3064.5× Citius Pharmaceuticals Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GWW | |
|---|---|---|
Market Cap | $20.01M | $61.32B |
Sector | Health | Technology |
52-Week High | $1.82 | $1.40K |
52-Week Low | $0.48 | $918.18 |
Enterprise Value | $16.23M | $63.53B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.
Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
